The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study

SABR波动模型 医学 放射治疗 阶段(地层学) 回顾性队列研究 肺癌 离格 队列 倾向得分匹配 放射外科 内科学 外科 肿瘤科 波动性(金融) 随机波动 金融经济学 经济 古生物学 生物
作者
Julianne Cynthia de Ruiter,Vincent van der Noort,Judi N.A. van Diessen,Egbert F. Smit,Ronald Damhuis,Koen J. Hartemink,M.I. Amir,H. van Berkum,H. Bertens,Manon Bindels,E. Bongers,R.C. Boshuizen,K. de Brake-de Jong,Jerry Braun,Frank J.C. van den Broek,Johan Bussink,Sebastian Canisius,Ronald Damhuis,M. Deelen,Jan P. Deroose
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:191: 107792-107792 被引量:4
标识
DOI:10.1016/j.lungcan.2024.107792
摘要

Objectives The aim of the Early-Stage LUNG cancer (ESLUNG) study was to compare outcomes after minimally invasive lobectomy (MIL) and stereotactic ablative radiotherapy (SABR) in patients with stage I non-small cell lung cancer (NSCLC). Materials and methods In this retrospective cohort study, patients with clinical stage I NSCLC (according to TNM7), treated in 2014–2016 with MIL or SABR, were included. 5-year overall survival (OS) and recurrence-free survival (RFS) were calculated and compared between patients treated with MIL and a propensity score (PS)-weighted SABR population with characteristics comparable to those of the MIL group. Results 1211 MIL and 972 SABR patients were included. Nodal upstaging occurred in 13.0 % of operated patients. 30-day mortality was 1.0 % after MIL and 0.2 % after SABR. After SABR, the 5-year regional recurrence rate (18.1 versus 14.2 %; HR 0.74, 95 % CI 0.58–0.94) and distant metastasis rate (26.2 versus 20.2 %; HR 0.72, 95 % CI 0.59–0.88) were significantly higher than after MIL, with similar local recurrence rate (13.1 versus 12.1 %; HR 0.90, 95 % CI 0.68–1.19). Unadjusted 5-year OS and RFS were 70.2 versus 40.3 % and 58.0 versus 25.1 % after MIL and SABR, respectively. PS-weighted, multivariable analyses showed no significant difference in OS (HR 0.89, 95 % CI 0.65–1.20) and better RFS after MIL (HR 0.70, 95 % CI 0.49–0.99). Conclusion OS was not significantly different between stage I NSCLC patients treated with MIL and the PS-weighted population of patients treated with SABR. For operable patients with stage I NSCLC, SABR could therefore be an alternative treatment option with comparable OS outcome. However, RFS was better after MIL due to fewer regional recurrences and distant metastases. Future studies should focus on optimization of patient selection for MIL or SABR to further reduce postoperative mortality and morbidity after MIL and nodal failures after SABR.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fbjbzj完成签到,获得积分10
1秒前
丝梦发布了新的文献求助10
1秒前
华仔的应助被开心德地采纳,获得10
2秒前
小马甲的应助被楠楠采纳,获得10
2秒前
热心市民范女士完成签到 ,获得积分10
2秒前
Nole的应助被DW采纳,获得10
3秒前
杜兰特工队完成签到,获得积分10
4秒前
受昂夫完成签到,获得积分10
4秒前
xiaojintongxue完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
7秒前
科研小李发布了新的文献求助10
8秒前
TFauthor发布了新的文献求助10
8秒前
8秒前
Qiuyajing完成签到 ,获得积分10
8秒前
9秒前
科研通AI65的应助被开心德地采纳,获得10
10秒前
闪闪乘风完成签到 ,获得积分10
10秒前
BIngo完成签到,获得积分10
10秒前
777发布了新的文献求助10
11秒前
Yan发布了新的文献求助10
11秒前
11秒前
共享精神的应助被抽烟酒牲采纳,获得10
12秒前
勤快的树懒完成签到,获得积分10
12秒前
13秒前
憨包发布了新的文献求助10
13秒前
13秒前
13秒前
辉099411完成签到,获得积分10
13秒前
yh发布了新的文献求助10
14秒前
丝梦完成签到,获得积分10
14秒前
14秒前
科研通AI65的应助被DW采纳,获得10
15秒前
15秒前
15秒前
真实的凉面完成签到,获得积分10
16秒前
16秒前
Nole的应助被克莱采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139